Jump to content

Henry Tazelaar

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Dr.WikiMD (talk | contribs) at 01:47, 29 September 2022. The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Henry D. Tazelaar is a lung, heart and transplant pathologist.

He obtained his B.A. at Calvin College then attended Rush Medical College of Rush University for his Doctor of Medicine (M.D). He then completed a residency in Pathology at Stanford University Medical Center, where he also obtained fellowship training in Surgical Pathology. While at Stanford he also did and NIH postdoctoral fellowship in heart and lung transplant pathology in the Laboratory of Dr. Margaret E. Billingham. He certified in Anatomic Pathology by the American Board of Pathology in 1988.

Tazelaar worked for 17 years at the Department of Pathology at the Mayo Clinic in Rochester, Minnesota and is currently a consultant at Mayo Clinic in Arizona and professor of Pathology, Mayo Clinic College of Medicine as well as being Vice Chair of Quality and Education in the Department of Laboratory Medicine and Pathology. Currently, Dr. Tazelaar is Chairman of the Department of Laboratory Medicine and Pathology at Mayo Clinic Scottsdale.

His areas of expertise are pulmonary pathology and cardiovascular pathology. He is nationally renowned as an expert in both these fields and lectures on a regular basis around the world. He is active in multiple pathology societies and has served in leadership positions in several (United States and Canadian Academy of Pathology, Pulmonary Pathology Society). He was President of the Pulmonary Pathology Society from 2004 to 2006.[1]

Writings

[edit]

He is one of the editors of a major textbook on the pathology of lung disease.,[2] which was reviewed in 2006 in the New England Journal of Medicine [3] and the American Journal of Surgical Pathology.[4]

Tazelaar was part of the team that described pulmonary lymphangioleiomyomatosis (a disease that occurs almost exclusively in women) in a male patient.[5] Another important contribution is his paper on acute eosinophilic pneumonia, in which he showed that the pathologic finding in these cases was diffuse alveolar damage with prominent eosinophils.[6]

He is a co-author of the lung and heart transplantation working formulations that provide guidelines to pathologists who interpret lung and heart biopsies from transplant patients.[7][8]

[edit]

References

[edit]
  1. ^ www.pulmonarypath.org Officer list
  2. ^ Myers JL, Tazelaar HD, Churg AM, Wright JL.(2005). Thurlbeck's Pathology of the Lung. Thieme Publishing Group. ISBN 1-58890-288-9
  3. ^ Franks TJ. Thurlbeck's Pathology of the Lung. N Engl J Med 2006; 354(13):1435-1436.
  4. ^ Butnor KJ. Thurlbeck's Pathology of the Lung. Am J Surg Pathol 2006; 30(4):548-549.
  5. ^ Aubry MC, Myers JL, Ryu JH, Henske EP, Logginidou H, Jalal SM, Tazelaar HD. Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 2000; 162(2 pt 1):749-752.
  6. ^ Tazelaar HD, Linz LJ, Colby TV, Myers JL, Limper AH. Acute eosinophilic pneumonia: histopathologic findings in nine patients. Am J Respir Crit Care Med 1997; 155(1):296-302.
  7. ^ Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, Glanville A, Gould FK, Magro C, Marboe CC, McNeil KD, Reed EF, Reinsmoen NL, Scott JP, Studer SM, Tazelaar HD, Wallwork JL, Westall G, Zamora MR, Zeevi A, Yousem SA. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007 Dec;26(12):1229-42. PubMed PMID 18096473.
  8. ^ Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.J Heart Lung Transplant. 2005 Nov;24(11):1710-20.